Clinical trials group continues to integrate acquisitions and eye new targets

A  Clearstream stent. Photograph: Eric Luke

Profit slips as Irish subsidiary of C R Bard accelerates investment in R&D

 Dr John Fox, chief executive, Merrion Pharmaceuticals. Photograph: Eric Luke / The Irish Times

Drug technology group takes €200,000 hit on Dublin premises it hopes to sell

Civitas is developing an inhaled form of the drug levadopa that is currently used by Parkinson’s patients in tablet form.

Alkermes spinoff also delivers dividend for drug technology group

 Pfizer has approached Actavis to express its interest in an acquisition that could allow the US drugmaker to move overseas and reduce taxes. Photo: Bloomberg

Acquisition could allow the US drugmaker to move overseas and reduce taxes

Merrion Pharmaceuticals chief executive John Fox. Photograph: Eric Luke

Elan spin-off re-emerges with impetus behind prospective therapy for breast cancer

Managing tax on gifts and inheritance

More articles